Ticker Details
4D Molecular Therapeutics, Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$476.92M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.61 | 3.59%
Avg Daily Range (30 D):	$0.28 | 3.46%
Avg Daily Range (90 D):	$0.38 | 3.94%

Institutional Daily Volume
Avg Daily Volume:	.44M
Avg Daily Volume (30 D):	.68M
Avg Daily Volume (90 D):	.78M

Trade Size
Avg Trade Size (Sh.):	74
Avg Trade Size (Sh.) (30 D):	73
Avg Trade Size (Sh.) (90 D):	75

Institutional Trades
Total Institutional Trades:	1,146
Avg Institutional Trade:	$1.8M
Avg Institutional Trade (30 D):	$.7M
Avg Institutional Trade (90 D):	$1.23M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.79M
Avg Closing Trade (30 D):	$.69M
Avg Closing Trade (90 D):	$1.16M
Avg Closing Volume:	104.36K

News

Nov 17, 2025 @ 11:00 AM 4DMT Appoints Kristian Humer as Chief Financial Of... Source: 4D Molecular Therapeutics

Oct 31, 2025 @ 3:02 AM 4DMT Announces Exclusive License Agreement with Ot... Source: 4D Molecular Therapeutics

Sep 11, 2025 @ 10:00 AM GenVivo Strengthens Oncology Leadership with Appoi... Source: Genvivo, Inc.

Aug 11, 2025 @ 12:16 PM 4dMT Revenue Jumps 200 Percent in Q2 Source: Jesterai

Aug 11, 2025 @ 12:00 PM 4DMT Reports Second Quarter 2025 Financial Results... Source: 4D Molecular Therapeutics

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-3.75	$-1.01	$-.98
Diluted EPS	$-3.75	$-1.01	$-.98
Revenue	$.12M	$.09M	$.02M
Gross Profit
Net Income / Loss	$-209.18M	$-56.88M	$-54.66M
Operating Income / Loss	$-230.38M	$-61.19M	$-59.46M
Cost of Revenue
Net Cash Flow	$-138.98M	$-28.6M	$-72.18M
PE Ratio